Is Amgen profitable in 2026?

Yes. Amgen guided FY2026 total revenue of $37.1 to $38.5 billion with non-GAAP EPS of $21.70 to $23.10 after Q1 2026 revenue hit $8.62 billion, up about 5.8% YoY, beating consensus estimates as of July 14, 2026.

Could AI replace Amgen?

No. AI like Amgen's AMPLIFY protein model speeds up discovery and clinical trial monitoring, but it cannot hold FDA regulatory liability, manufacture biologics at scale, or replace Amgen's patent estate and payer relationships, per Amgen's own May 2026 statements on AI-enabled clinical development.

Is Amgen laying off workers in 2026?

Amgen cut 22 jobs at its Horizon Therapeutics Rockville, MD site via a WARN notice effective May 8, 2026, even as total headcount grew to roughly 31,500 to 31,723 employees by December 2025, up about 11 to 12.5% YoY, per Macrotrends and Revelio Labs data.

Who is Amgen's biggest competitor in obesity drugs?

Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) dominate the obesity market with first-mover advantage; Amgen's MariTide is a Phase 3 challenger not yet FDA-approved as of mid-2026, running nine global Phase 3 MARITIME studies.

Amgen is a publicly traded, widely held independent company with no controlling parent, trading on Nasdaq as AMGN with a market cap around $197 to $198 billion as of July 20, 2026, and is a Dow Jones Industrial Average constituent.

How is Amgen's legacy drug business declining?

Amgen's XGEVA sales fell 20% YoY in Q4 2025 to $447 million due to biosimilar competition, while Enbrel faces IRA Medicare price negotiation effective January 2026 and state price-cap actions, though Amgen won a preliminary injunction against Colorado's cap on July 1, 2026.

Pharma and healthcare groups · United States

Amgen

amgen.com ↗

Amgen makes biologic drugs for bone disease, cancer, and inflammation worldwide.

Hard to displace

Assessed 20 July 2026 · Evidence as of 20 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 20 July 2026 · Checkable from August 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings with MariTide Phase 3 readouts

The call

Amgen's legacy drugs are losing ground to biosimilar copies, but newer growth drivers already make up 70% of sales and FDA approval keeps the business intact.

Amgen makes prescription medicines and biologics, including treatments for bone disease, heart disease, and cancer. It is hard to copy because the U.S. Food and Drug Administration approval process takes years, the company owns many patents, and manufacturing these complex drugs requires specialized factories and expertise that take time and money to build. Competitors like Eli Lilly and Novo Nordisk are winning in weight-loss drugs with Zepbound and Wegovy, and Amgen's obesity drug MariTide is still in testing, so success in that market could be a major change.

Why

AI pressure: None apparent. AI tools speed up drug discovery research inside Amgen but no AI product replaces biologic manufacturing or FDA approval. Could AI do the core job? Unlikely.

Bigger players: Eli Lilly and Novo Nordisk in obesity; Amneal, Biocon, Sandoz in biosimilars. Lilly's Zepbound and Novo's Wegovy own obesity now while Amgen's MariTide is still in Phase 3, unapproved. Could a giant copy it? No, they are blocked.

What protects it. FDA approval, biologics manufacturing scale, and a patent estate with 34 Prolia/XGEVA patents keep copies out for years.

What would change this call

MariTide Phase 3 obesity/diabetes data readouts and any FDA filing through 2026. Shows whether Amgen can challenge Lilly and Novo Nordisk in obesity beyond current legacy erosion.
Outcome of MDL 3138 Amgen v. Amneal biosimilar patent litigation and Delaware verdict appeal. Indicates how much legal protection remains for Amgen's aging Prolia/XGEVA franchises.
Pace of XGEVA and Prolia revenue decline in quarterly earnings through 2026. Shows whether biosimilar erosion is accelerating faster than new drug growth can offset.

Key numbers

$197B market value (2026)
Revenue over $37B, growing 9-10% YoY (2026)
XGEVA sales down 20% YoY from biosimilar erosion (2026)

Named risks

Biosimilar erosion of legacy franchises like Prolia and XGEVA expected to accelerate in 2026. Severity: medium
IRA Medicare price negotiation on Enbrel and state price-cap litigation create pricing pressure. Severity: medium
MariTide obesity candidate unapproved; Phase 3 readouts pending with uncertain FDA outcome. Severity: medium
Potentially material IRS audit adjustment for tax years 2016-2018 flagged as risk factor. Severity: medium
Multiple active patent infringement suits including Harbour BioMed verdict could increase liability. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Eli Lilly	losing to	Zepbound dominates obesity market; Amgen's MariTide still Phase 3, unapproved as of mid-2026
Novo Nordisk	losing to	Wegovy holds first-mover advantage in obesity vs Amgen's pipeline candidate MariTide
Biocon Biologics	contesting	Amgen enforced 34 Prolia/XGEVA patents in litigation against Biocon, settled 2026-06-02
Sandoz, Amneal, Henlius	contesting	Biosimilar makers erode Amgen legacy franchises post-patent expiry, MDL 3138 ongoing as of 2026-06-04
Harbour BioMed	losing to	Delaware jury awarded Harbour BioMed $20.2 million against Amgen/Teneobio, June 2026, could triple to $60.6 million
Sanofi/Regeneron	contesting	Ongoing Repatha vs Praluent PCSK9-class patent battle per juve-patent chronology

Questions people ask

Is Amgen profitable in 2026?: Yes. Amgen guided FY2026 total revenue of $37.1 to $38.5 billion with non-GAAP EPS of $21.70 to $23.10 after Q1 2026 revenue hit $8.62 billion, up about 5.8% YoY, beating consensus estimates as of July 14, 2026.
Could AI replace Amgen?: No. AI like Amgen's AMPLIFY protein model speeds up discovery and clinical trial monitoring, but it cannot hold FDA regulatory liability, manufacture biologics at scale, or replace Amgen's patent estate and payer relationships, per Amgen's own May 2026 statements on AI-enabled clinical development.
Is Amgen laying off workers in 2026?: Amgen cut 22 jobs at its Horizon Therapeutics Rockville, MD site via a WARN notice effective May 8, 2026, even as total headcount grew to roughly 31,500 to 31,723 employees by December 2025, up about 11 to 12.5% YoY, per Macrotrends and Revelio Labs data.
Who is Amgen's biggest competitor in obesity drugs?: Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) dominate the obesity market with first-mover advantage; Amgen's MariTide is a Phase 3 challenger not yet FDA-approved as of mid-2026, running nine global Phase 3 MARITIME studies.
Who owns Amgen?: Amgen is a publicly traded, widely held independent company with no controlling parent, trading on Nasdaq as AMGN with a market cap around $197 to $198 billion as of July 20, 2026, and is a Dow Jones Industrial Average constituent.
How is Amgen's legacy drug business declining?: Amgen's XGEVA sales fell 20% YoY in Q4 2025 to $447 million due to biosimilar competition, while Enbrel faces IRA Medicare price negotiation effective January 2026 and state price-cap actions, though Amgen won a preliminary injunction against Colorado's cap on July 1, 2026.

Timeline

2026-07-01Amgen wins preliminary injunction blocking Colorado's Enbrel price cap in Amgen Inc. v. Mizner
2026-06-04MDL 3138, In re Amgen v. Amneal biosimilar patent case, ongoing in D.N.J.
2026-05-19FDA names Amgen and AstraZeneca first sponsors in real-time AI-monitored clinical trial pilot
2026-05-19Amgen announces CFO Peter Griffith's retirement; Thomas Dittrich to succeed him September 1, 2026
2026-04-22Amgen announces retirement of inaugural CTO David Reese
2026-03-10Amgen cuts 22 jobs at Horizon Therapeutics Rockville, MD site via WARN notice
2026-02-03Amgen reports FY2025 revenue of $36.8 billion, up 10% YoY
2026-01-06Amgen acquires Dark Blue Therapeutics for up to $840 million to bolster oncology pipeline
2025-12-01Amgen details AMPLIFY protein language model co-developed with Mila
2025-10-01Amgen launches AmgenNow, a direct-to-patient access program

Revision history

20 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Vertex Pharmaceuticals Tenet Healthcare Intuitive Surgical

More in Pharma and healthcare groups →